Cases


  • All
  • Antitrust Litigation
  • Consumer Protection Litigation
  • Securities Litigation
  • Shareholder Derivative Litigation
  • Shareholder Merger Litigation
  • Employment Litigation
  • Pharmaceutical Litigation
  • Personal Injury Litigation

23 Jul 2020

In re Bystolic Antitrust Litig., No. 20-cv-05735 (S.D.N.Y)

In the Bystolic case, Faruqi & Faruqi represents a proposed class of direct purchasers of Forest Laboratories' (now AbbVie) blood pressure drug, Bystolic. The complaint alleges that Forest entered into reverse payment agreements with several would-be ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

29 Mar 2020

In re EpiPen Direct Purchaser Litig., No. 20-cv-0827 (D. Minn.)

In the EpiPen case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Mylan's EpiPen, an epinephrine auto-injector used to treat anaphylaxis (i.e. allergic reactions). The complaint alleges that Mylan ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

02 Aug 2019

In re Seroquel XR (Extended Release Quetiapine Fumarate) Litig., No. 20-cv-01076 (D. Del.)

In the Seroquel case, Faruqi & Faruqi represents a proposed class of direct purchasers of AstraZeneca's Seroquel XR, a prescription drug treatment for schizophrenia, bipolar disorder, and depression. The complaint alleges that AstraZeneca entered into ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

22 Jun 2018

In re Novartis and Par Antitrust Litig., No. 18-cv-04361 (S.D.N.Y.)

In the Exforge case, Faruqi & Farqui represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the hypertension drug, Exforge. The complaint alleges that Novartis entered into a reverse payment agreement with Par to delay Par's ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

07 Feb 2018

In re Zetia (Ezetimibe) Antitrust Litig., No. 18-md-02836 (E.D. Va.)

In the Zetia case, Faruqi & Faruqi represents a class of direct purchasers of Merck & Co.'s Zetia (ezetimibe), a drug used to treat high cholesterol. The case alleges that Merck entered into an unlawful reverse payment settlement with generic manufacturers ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

11 Jan 2017

In re Intuniv Antitrust Litig., No. 16-cv-12653 (D. Mass.)

In the Intuniv case, Faruqi & Faruqi represents a class of direct purchasers of Shire's Intuniv (guanfacine), a prescription drug used to treat attention deficit hyperactivity disorder. The class also includes direct purchasers of generic versions of ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

05 Aug 2016

In re Generic Pharmaceuticals Pricing Antitrust Litig., MDL No. 2724 (E.D. Pa.)

Faruqi & Faruqi represents a proposed class of generic drug purchasers in this action alleging that dozens of generic pharmaceutical manufacturers engaged in an unlawful scheme to fix, maintain, and stabilize prices, rig bids, and engage in market and ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

12 Nov 2015

In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)

In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham's Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class ...

Joseph T. Lukens, Peter Kohn at New York office

Read more

05 Apr 2013

In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)

In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories' triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6). Faruqi & Faruqi filed the first direct ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

05 Mar 2013

In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., No. 13-cv-2445 (E.D. Pa.)

In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a class of direct purchasers of Reckitt Benckiser's opioid addiction drug, Suboxone. The class alleges that Reckitt took several actions to suppress competition from generic ...

Joseph T. Lukens, Peter Kohn at Pennsylvania office

Read more

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania